CRISPR-Cas9: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 79: Line 79:
'''Structural Basis for the Distinct PAM Specificities'''
'''Structural Basis for the Distinct PAM Specificities'''


A structural comparison of SaCas9, SpCas9, and AnCas9 revealed
A structural comparison of SaCas9, SpCas9, and AnCas9 revealed that, despite the lack of sequence homology, their PI domains share a similar protein fold. The PI domains consist of the TOPO domain, comprising a three-stranded anti-parallel β-sheet (β1–β3) flanked by several α-helices, and the C-terminal domain, comprising a twisted six-stranded anti-parallel β-sheet (β4–β9) (β7 in SpCas9 adopts a loop conformation). In both SaCas9 and SpCas9, the major groove of the PAM duplex is read by the β5–β7 region in their PI domains. The 3rd G in the 5'-NNGRRT-3' PAM is recognized by Arg1015 in SaCas9 , whereas the 3rd G in the 5'-NGG-3' PAM is recognized by Arg1335 in SpCas9 in a similar manner. However, there are notable differences in the PI domains of SaCas9 and SpCas9, consistent with their distinct PAM specificities. Arg1333 of SpCas9, which recognizes the 2nd G in the 5'-NGG-3' PAM, is replaced with Pro1013 in SaCas9. In addition, SpCas9 lacks the amino acid residues equivalent to Asn985/Asn986 (β5) and Arg991 (β6) of SaCas9, because the b5–b6 region of SpCas9 is shorter than that of SaCas9. Moreover, Asn985, Asn986, Arg991, and Arg1015 in SaCas9 are replaced with Asp1030, Thr1031, Lys1034, and Lys1061 in AnCas9, respectively, suggesting that the PAM of AnCas9 is different from those of SaCas9 and SpCas9 (although the sequence remains unknown). Together, these structural findings demonstrate that the distinct PAM specificities of the Cas9 orthologs are primarily defined by the specific differences in the PAM-interacting residues in the PI domains.
that, despite the lack of sequence homology, their PI
domains share a similar protein fold (Figures 5D and 5E, and
Figure S6A). The PI domains consist of the TOPO domain,
comprising a three-stranded anti-parallel b sheet (b1–b3) flanked
by several a helices, and the C-terminal domain, comprising a
twisted six-stranded anti-parallel b sheet (b4–b9) (b7 in SpCas9
adopts a loop conformation) (Figures 5D and 5E and Figure S6A).
In both SaCas9 and SpCas9, the major groove of the PAM
duplex is read by the b5–b7 region in their PI domains (Figures
5D and 5E). The 3rd G in the 50
-NNGRRT PAM-30 is recognized
by Arg1015 in SaCas9 (Figure 5D), whereas the 3rd G in the
50
-NGG-30 PAM is recognized by Arg1335 in SpCas9 in a similar
manner (Figure 5E). However, there are notable differences in the
PI domains of SaCas9 and SpCas9, consistent with their distinct
PAM specificities. Arg1333 of SpCas9, which recognizes the 2nd
G in the 50
-NGG-30 PAM, is replaced with Pro1013 in SaCas9
(Figures 5D and 5E and Figure S3). In addition, SpCas9 lacks the amino acid residues equivalent to Asn985/Asn986 (b5) and
Arg991 (b6) of SaCas9, because the b5–b6 region of SpCas9 is
shorter than that of SaCas9 (Figures 5D and 5E and Figure S3).
Moreover, Asn985, Asn986, Arg991, and Arg1015 in SaCas9
are replaced with Asp1030, Thr1031, Lys1034, and Lys1061 in
AnCas9, respectively (Figure S6A), suggesting that the PAM of
AnCas9 is different from those of SaCas9 and SpCas9 (although
the sequence remains unknown). Together, these structural findings
demonstrate that the distinct PAM specificities of the Cas9
orthologs are primarily defined by the specific differences in the
PAM-interacting residues in the PI domains.


=See aslo=
=See aslo=

Revision as of 17:02, 30 August 2018

SEE ALSO CRISPR-Cas

Background

Highlights

  • CRISPR-Cas9 is a powerful tool to modulate transcription in wide range of cell types.
  • An expanding set of CRISPR-based transcription effectors is available.
  • Gene networks can be efficiently probed and modified for biotechnology applications.[1]

CRISPR-Cas9 has recently emerged as a promising system for multiplexed genome editing as well as epigenome and transcriptome perturbation. Due to its specificity, ease of use and highly modular programmable nature, it has been widely adopted for a variety of applications such as genome editing, transcriptional inhibition and activation, genetic screening, DNA localization imaging, and many more. In this review, we will discuss non-editing applications of CRISPR-Cas9 for transcriptome perturbation, metabolic engineering, and synthetic biology.[1]

Since the early days of genetic engineering there has been a need for control of gene expression. Naturally occurring transcription factors (TFs) have traditionally been used to achieve this goal (reviewed in [2]). However, their limited DNA binding sequence space required installing specific sequences within the transcription regulatory elements of the target genes. This can be technically difficult and may have unintended consequences on gene expression. Zinc fingers (ZFs) and transcription activator-like effectors (TALEs) were developed to overcome the fixed binding sequence requirements of native TFs. However, both ZFs and TALEs have significant limitations. ZFs have complicated design criteria and large highly repetitive TALE genes are difficult to synthesize and clone (reviewed in [3][4]). These challenges have recently been overcome using CRISPR-Cas9 based TFs. The biochemical properties of CRISPR-Cas9 based TFs that enable such flexibility and describe their applications to synthetic gene circuit design and multi-plexed perturbation of native gene networks.[1]

Transcriptional regulation with CRISPR-Cas9

Figure 1. Overview of Cas9 nuclease and dCas9-based transcription factors. (a) Wild-type Cas9 endonuclease guided by crRNA:tracrRNA to a specific site in DNA creates a double-stranded DNA break. (b) dCas9, nuclease deactivated mutant of Cas9, is an RNA programmable DNA binding protein. It can act as a steric repressor of transcription in prokaryotes and eukaryotes. sgRNA is an artificial chimeric molecule consisting of crRNA and tracrRNA molecules connected with a short loop. (c) dCas9 fusion with various transcription effectors can be used to repress or activate transcription. (d) Effector domains can be recruited by sgRNA in addition to dCas9 for enhanced activity. (e) sgRNA can be modified with specific protein binding hairpins to concurrently recruit repressor or activator domains in the same cell.[1]

Cas9 is a key protein of bacterial Type II CRISPR adaptive immune system (reviewed in [5]). In its native context, Cas9 is an RNA-guided endonuclease that is responsible for targeted degradation of the invading foreign DNA–plasmids and phages. Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with two small non-coding RNAs: CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) (Figure 1a). In the less common class 2 CRISPR-Cas systems (types II, V, and VI), which are almost completely restricted to bacteria, the effector complex is represented by a single multidomain protein [6]. The best-characterized class 2 effector is Cas9 (type II), the RNA-dependent endonuclease that contains two unrelated nuclease domains, HNH and RuvC, that are responsible for the cleavage of the target and the displaced strand, respectively, in the crRNA–target DNA complex (, 4zt0). The type II loci also encode a trans-acting CRISPR RNA (tracrRNA) that evolved from the corresponding CRISPR repeat and is essential for pre-crRNA processing and target recognition in type II systems. Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with these 2 small non-coding RNAs: crRNA and tracrRNA. By elegant engineering, (4zt9[7]) that too efficiently directs Cas9 protein to DNA targets encoded within the guide sequence of sgRNA [8]:

Examples of 3D structures of single guide RNA (sgRNA)

The , termed the guide sequence, adjacent to a [8][9]. Despite this, a [8][10][11][12], more so within the 5’ proximal position of the guide sequence.

  • (5f9r)[15].
  • .
  • - place of accurate, precise, and programmable DNA cleavage.
  • (sgRNA is not shown).

In the type II-A system, the Cas9-tracrRNA complex and Csn2 are involved in spacer acquisition along with the Cas1-Cas2 complex [16][17]; the involvement of Cas9 in adaptation is likely to be a general feature of type II systems. Although the key residues of Cas9 involved in PAM recognition are dispensable for spacer acquisition, they are essential for the incorporation of new spacers with the correct PAM sequence [17]. The involvement of Cas9 in PAM recognition and protospacer selection [17] suggests that in type II systems Cas1 may have lost this role.

Cas9 nuclease can be converted into (PDB entry 4zt9), an RNA-programmable DNA-binding protein, by (Figure 1b) [7][1][8][9].

In the simplest case, dCas9 can repress transcription by sterically interfering with transcription initiation or elongationby being targeted to the gene of interest with a properly chosen sgRNA [8][9][10][11][18][19][20][21][22]. The repression strength is strongly dependent on the position with respect to the target promoter as well as the nature of promoter itself [10][11][18][19]. In prokaryotes, repression of up to 1000-fold was achieved when targeting dCas9 to either DNA strand within a promoter or to the non-template DNA strand downstream. However, in eukaryotic cells such steric repression is weaker: only up to 2-fold and 20-fold repression was observed with natural promoters in mammalian and yeast cells correspondingly[10][20][21]. As a notable exception, synthetic promoters specifically constructed for direct repression by dCas9 can be repressed up to 100-fold in mammalian cells[22].

Cas9-sgRNA-target DNA complexes from Streptococcus pyogenes:

Other representatives: 5y36, 4un3.

Crystal Structure of Staphylococcus aureus Cas9[23]

The RNA-guided DNA endonuclease Cas9 cleaves double-stranded DNA targets with a protospacer adjacent motif (PAM) and complementarity to the guide RNA. Recently, we harnessed Staphylococcus aureus Cas9 (SaCas9), which is significantly smaller than Streptococcus pyogenes Cas9 (SpCas9), to facilitate efficient in vivo genome editing. Here, the crystal structures of SaCas9 in complex with a single guide RNA (sgRNA) and its double stranded DNA targets, containing the 5'-TTGAAT-3' PAM and the 5'-TTGGGT-3' PAM, at 2.6 and 2.7 A˚ resolutions, respectively, were reported. The structures revealed the mechanism of the relaxed recognition of the 5'-NNGRRT-3' PAM by SaCas9. A structural comparison of SaCas9 with SpCas9 highlighted both structural conservation and divergence, explaining their distinct PAM specificities and orthologous sgRNA recognition.

Overall Structure of the SaCas9–sgRNA–Target DNA Complex

The (residues 1–1053; N580A/C946A) in complex with a 73-nucleotide (nt) sgRNA, a 28-nt target DNA strand and an 8-nt non-target DNA strand, containing the 5'-TTGAAT-3' PAM was solved (5czz). SaCas9 adopts a consisting of a REC lobe (residues 41–425) and a NUC lobe (residues 1–40 and 435–1053). The by an arginine-rich bridge helix (residues 41–73) and a linker loop (residues 426–434). The the RuvC (residues 1–40, 435–480 and 650–774), HNH (residues 520–628), WED (residues 788–909), and PI (residues 910–1053) domains. The can be divided into a Topoisomerase-homology (TOPO) domain and a C-terminal domain (CTD). The three separate motifs (RuvC-I–III) and interacts with the HNH and PI domains. The is connected to RuvC-II and RuvC-III by the L1 (residues 481–519) and L2 (residues 629–649) linker regions, respectively. The active site of the HNH domain is distant from the cleavage site in the target DNA strand (the phosphodiester linkage between dC3 and dA4), indicating that the present structure represents the inactive state. The WED and RuvC domains are connected by a loop (residues 775–787). Previous structural studies revealed that SpCas9 undergoes conformational rearrangements upon guide RNA binding, to form the central channel between the REC and NUC lobes. In the absence of the guide RNA, SpCas9 and AnCas9 adopt a closed conformation, where the active site of the HNH domain is covered by the RuvC domain. In contrast, the ternary and quaternary complex structures of SpCas9 adopt an open conformation and have the central channel, which accommodates the guide RNA–target DNA heteroduplex (referred to as the guide:target heteroduplex). The present , suggesting that the guide RNA-induced conformational

activation is conserved between SaCas9 and SpCas9. A structural comparison between SaCas9 and SpCas9 revealed that, although their overall architectures are similar, there are notable differences in their REC, WED, and PI domains, as described in detail below, thereby explaining the significant sequence and size differences of the two Cas9 orthologs.

Structure of the sgRNA–Target DNA Complex

The SaCas9 sgRNA consists of the guide region (G1–C20),repeat region (G21–G34), tetraloop (G35–A38), anti-repeat region (C39–C54), stem loop 1 (A56–G68), and single-stranded linker (U69–U73), with A55 connecting the anti-repeat region and stem loop 1. U73 at the 3' end is disordered in the present structure. The guide region (G1–C20) and the target DNA strand (dG1–dC20) form the , whereas the target DNA strand (dC(8)–dA(1)) and the non-target DNA strand (dT1*–dG8*) form a (referred to as the PAM duplex). The repeat (G21–G34) and anti-repeat (C39–C54) regions form a distorted duplex (referred to as the ) via 13 Watson-Crick base pairs. is formed via three Watson-Crick base pairs (G57:C67–C59:G65) and two non-canonical base pairs (A56:G68 and A60:A63). U64 does not base pair with A60 and is flipped out of the stem loop. The N1 and N6 of A63 hydrogen bond with the 2'-OH and N3 of A60, respectively. G68 stacks with G57:C67, with the G68 N2 interacting with the backbone phosphate group between A55 and A56. A55 adopts the syn conformation, and its adenine base stacks with U69. In addition, the N1 of A55 hydrogen bonds with the 2'-OH of G68, thus stabilizing the basal region of stem loop 1. An adenosine residue immediately after the repeat:anti-repeat duplex is highly conserved among CRISPR-Cas9 systems, and the equivalent adenosine in the SpCas9 sgRNA, A51, also adopts the syn conformation, suggesting that these adenosine residues play conserved key roles in connecting the repeat:anti-repeat duplex and stem loop 1.

Recognition Mechanism of the Guide:Target Heteroduplex

The formed between the REC and NUC lobes. The sugar-phosphate backbone of the PAM-distal region (A3–U6) of the sgRNA interacts with the . In SpCas9 and SaCas9, the RNA–DNA base pairing in the 8 bp PAM-proximal ‘‘seed’’ region in the guide:target heteroduplex is critical for Cas9-catalyzed DNA cleavage. Consistent with this, the phosphate backbone of the sgRNA seed region (C13–C20) is extensively recognized , as in the case of SpCas9. These structural observations explain the RNA-guided DNA targeting mechanism of SaCas9. The C-terminal region of the REC lobe interacts with the PAM-distal region of the heteroduplex, whereas the N-terminal region of the REC lobe interacts with the repeat:anti-repeat duplex and the PAM-proximal region of the heteroduplex. Notably, the C-terminal region of the REC lobe of SaCas9 shares structural similarity with those of SpCas9 (PDB: 4un3, 26% identity, rmsd of 1.9 A˚ for 177 equivalent Ca atoms) and AnCas9 (PDB: 4oge, 16% identity, rmsd of 3.2 A˚ for 167 equivalent Ca atoms). These structural findings suggested that the Cas9 orthologs recognize the PAM-distal region of the guide:target heteroduplex in a similar manner.

Recognition Mechanism of the sgRNA Scaffold

The . Consistent with our data showing that the distorted repeat:anti-repeat duplex is critical for Cas9-catalyzed DNA cleavage, the . The 2'-OH of C30 hydrogen bonds with , and the backbone phosphate groups of U31, C45, and U46 interact with , respectively. These structural observations explain the structure-dependent recognition of the repeat:anti-repeat duplex by SaCas9. Stem loop 1 is recognized by the bridge helix and the REC lobe. The phosphate backbone of interacts with the bridge helix () and the REC lobe (). The . The flipped-out , respectively. A55 is extensively recognized by the phosphate lock loop. The , respectively. . The phosphate backbone of the , and the nucleobase of on the bridge helix.


Recognition Mechanism of the 5'-NNGRRT-3' PAM

SaCas9 recognizes the 5'-NNGRRN-3' PAM, with a preference for a thymine base at the 6th position, which is distinct from the 5'-NGG-3' PAM of SpCas9. In the present structures containing either the or the 5'-TTGGGT-3' PAM, the PAM duplex is sandwiched between the WED and PI domains, and the PAM in the non-target DNA strand is read from the major groove side by the PI domain. dT1* and dT2* do not directly contact the protein. Consistent with the observed requirement for the 3rd G in the 5'-NNGRRT-3' PAM, the O6 and N7 of dG3* form bidentate hydrogen bonds with the side chain of Arg1015, which is anchored via salt bridges with Glu993 in both complexes. In the 5'-TTGAAT-3' PAM complex, the , respectively. In addition, the N6 of dA5* forms a water-mediated hydrogen bond with Asn985. Similarly, in the 5'-TTGGGT-3' PAM complex, the N7 atoms of dG4* and dG5* form direct and water-mediated hydrogen bonds with Asn985 and Asn985/Asn986/Arg991, respectively. The O6 of dG5* forms a water-mediated hydrogen bond with Asn985. These structural features explain the ability of SaCas9 to recognize the purine nucleotides at positions 4 and 5 in the 5'-NNGRRT-3' PAM. The O4 of dT6* hydrogen bonds with Arg991, explaining the preference of SaCas9 for the 6th T in the 5'-NNGRRT-3' PAM. Single alanine mutations of these PAM-interacting residues reduced the cleavage activity in vivo, and double mutations abolished the activity, confirming the importance of Asn985, Asn986, Arg991, Glu993, and Arg1015 for PAM recognition. In addition, the phosphate backbone of the PAM duplex is recognized from the minor groove side by the WED domain (Tyr789, Tyr882, Lys886, Ans888, Ala889, and Leu909), in a distinct manner from that in SpCas9. Together, these structural and functional data have revealed the mechanism underlying the relaxed recognition of the 5'-NNGRRT-3' PAM by SaCas9.

Structural Basis for the Distinct PAM Specificities

A structural comparison of SaCas9, SpCas9, and AnCas9 revealed that, despite the lack of sequence homology, their PI domains share a similar protein fold. The PI domains consist of the TOPO domain, comprising a three-stranded anti-parallel β-sheet (β1–β3) flanked by several α-helices, and the C-terminal domain, comprising a twisted six-stranded anti-parallel β-sheet (β4–β9) (β7 in SpCas9 adopts a loop conformation). In both SaCas9 and SpCas9, the major groove of the PAM duplex is read by the β5–β7 region in their PI domains. The 3rd G in the 5'-NNGRRT-3' PAM is recognized by Arg1015 in SaCas9 , whereas the 3rd G in the 5'-NGG-3' PAM is recognized by Arg1335 in SpCas9 in a similar manner. However, there are notable differences in the PI domains of SaCas9 and SpCas9, consistent with their distinct PAM specificities. Arg1333 of SpCas9, which recognizes the 2nd G in the 5'-NGG-3' PAM, is replaced with Pro1013 in SaCas9. In addition, SpCas9 lacks the amino acid residues equivalent to Asn985/Asn986 (β5) and Arg991 (β6) of SaCas9, because the b5–b6 region of SpCas9 is shorter than that of SaCas9. Moreover, Asn985, Asn986, Arg991, and Arg1015 in SaCas9 are replaced with Asp1030, Thr1031, Lys1034, and Lys1061 in AnCas9, respectively, suggesting that the PAM of AnCas9 is different from those of SaCas9 and SpCas9 (although the sequence remains unknown). Together, these structural findings demonstrate that the distinct PAM specificities of the Cas9 orthologs are primarily defined by the specific differences in the PAM-interacting residues in the PI domains.

See aslo

Drag the structure with the mouse to rotate

ReferencesReferences

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Didovyk A, Borek B, Tsimring L, Hasty J. Transcriptional regulation with CRISPR-Cas9: principles, advances, and applications. Curr Opin Biotechnol. 2016 Aug;40:177-84. doi: 10.1016/j.copbio.2016.06.003. Epub, 2016 Jun 23. PMID:27344519 doi:http://dx.doi.org/10.1016/j.copbio.2016.06.003
  2. ↑ Brophy JA, Voigt CA. Principles of genetic circuit design. Nat Methods. 2014 May;11(5):508-20. doi: 10.1038/nmeth.2926. PMID:24781324 doi:http://dx.doi.org/10.1038/nmeth.2926
  3. ↑ Straubeta A, Lahaye T. Zinc fingers, TAL effectors, or Cas9-based DNA binding proteins: what's best for targeting desired genome loci? Mol Plant. 2013 Sep;6(5):1384-7. doi: 10.1093/mp/sst075. Epub 2013 May 29. PMID:23718948 doi:http://dx.doi.org/10.1093/mp/sst075
  4. ↑ Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014 Apr;32(4):347-55. doi: 10.1038/nbt.2842. Epub 2014 Mar 2. PMID:24584096 doi:http://dx.doi.org/10.1038/nbt.2842
  5. ↑ Marraffini LA. CRISPR-Cas immunity in prokaryotes. Nature. 2015 Oct 1;526(7571):55-61. doi: 10.1038/nature15386. PMID:26432244 doi:http://dx.doi.org/10.1038/nature15386
  6. ↑ Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJ, Charpentier E, Haft DH, Horvath P, Moineau S, Mojica FJ, Terns RM, Terns MP, White MF, Yakunin AF, Garrett RA, van der Oost J, Backofen R, Koonin EV. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015 Nov;13(11):722-36. doi: 10.1038/nrmicro3569. Epub 2015, Sep 28. PMID:26411297 doi:http://dx.doi.org/10.1038/nrmicro3569
  7. ↑ 7.0 7.1 7.2 7.3 Jiang F, Zhou K, Ma L, Gressel S, Doudna JA. STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. Science. 2015 Jun 26;348(6242):1477-81. doi: 10.1126/science.aab1452. PMID:26113724 doi:http://dx.doi.org/10.1126/science.aab1452
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829. Epub 2012, Jun 28. PMID:22745249 doi:http://dx.doi.org/10.1126/science.1225829
  9. ↑ 9.0 9.1 9.2 Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2579-86. Epub 2012 Sep 4. PMID:22949671 doi:http://dx.doi.org/10.1073/pnas.1208507109
  10. ↑ 10.0 10.1 10.2 10.3 Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013 Feb 28;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022. PMID:23452860 doi:http://dx.doi.org/10.1016/j.cell.2013.02.022
  11. ↑ 11.0 11.1 11.2 Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 2013 Aug;41(15):7429-37. doi: 10.1093/nar/gkt520. Epub 2013, Jun 12. PMID:23761437 doi:http://dx.doi.org/10.1093/nar/gkt520
  12. ↑ Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. 2014 Jul;32(7):677-83. doi: 10.1038/nbt.2916. Epub 2014 May 18. PMID:24837660 doi:http://dx.doi.org/10.1038/nbt.2916
  13. ↑ Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E, Doudna JA. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science. 2014 Feb 6. PMID:24505130 doi:http://dx.doi.org/10.1126/science.1247997
  14. ↑ Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, Ishitani R, Zhang F, Nureki O. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014 Feb 27;156(5):935-49. doi: 10.1016/j.cell.2014.02.001. Epub 2014 Feb, 13. PMID:24529477 doi:http://dx.doi.org/10.1016/j.cell.2014.02.001
  15. ↑ Jiang F, Taylor DW, Chen JS, Kornfeld JE, Zhou K, Thompson AJ, Nogales E, Doudna JA. Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science. 2016 Jan 14. pii: aad8282. PMID:26841432 doi:http://dx.doi.org/10.1126/science.aad8282
  16. ↑ Wei Y, Terns RM, Terns MP. Cas9 function and host genome sampling in Type II-A CRISPR-Cas adaptation. Genes Dev. 2015 Feb 15;29(4):356-61. doi: 10.1101/gad.257550.114. PMID:25691466 doi:http://dx.doi.org/10.1101/gad.257550.114
  17. ↑ 17.0 17.1 17.2 Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, Marraffini LA. Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature. 2015 Mar 12;519(7542):199-202. doi: 10.1038/nature14245. Epub 2015 Feb, 18. PMID:25707807 doi:http://dx.doi.org/10.1038/nature14245
  18. ↑ 18.0 18.1 Nielsen AA, Voigt CA. Multi-input CRISPR/Cas genetic circuits that interface host regulatory networks. Mol Syst Biol. 2014 Nov 24;10:763. doi: 10.15252/msb.20145735. PMID:25422271
  19. ↑ 19.0 19.1 Didovyk A, Borek B, Hasty J, Tsimring L. Orthogonal Modular Gene Repression in Escherichia coli Using Engineered CRISPR/Cas9. ACS Synth Biol. 2016 Jan 15;5(1):81-8. doi: 10.1021/acssynbio.5b00147. Epub 2015 , Sep 30. PMID:26390083 doi:http://dx.doi.org/10.1021/acssynbio.5b00147
  20. ↑ 20.0 20.1 Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013 Jul 18;154(2):442-51. doi: 10.1016/j.cell.2013.06.044. Epub 2013 Jul, 11. PMID:23849981 doi:http://dx.doi.org/10.1016/j.cell.2013.06.044
  21. ↑ 21.0 21.1 Farzadfard F, Perli SD, Lu TK. Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth Biol. 2013 Oct 18;2(10):604-13. doi: 10.1021/sb400081r. Epub 2013 Sep, 11. PMID:23977949 doi:http://dx.doi.org/10.1021/sb400081r
  22. ↑ 22.0 22.1 Kiani S, Beal J, Ebrahimkhani MR, Huh J, Hall RN, Xie Z, Li Y, Weiss R. CRISPR transcriptional repression devices and layered circuits in mammalian cells. Nat Methods. 2014 Jul;11(7):723-6. doi: 10.1038/nmeth.2969. Epub 2014 May 5. PMID:24797424 doi:http://dx.doi.org/10.1038/nmeth.2969
  23. ↑ Nishimasu H, Cong L, Yan WX, Ran FA, Zetsche B, Li Y, Kurabayashi A, Ishitani R, Zhang F, Nureki O. Crystal Structure of Staphylococcus aureus Cas9. Cell. 2015 Aug 27;162(5):1113-26. doi: 10.1016/j.cell.2015.08.007. PMID:26317473 doi:http://dx.doi.org/10.1016/j.cell.2015.08.007

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=CRISPR-Cas9&oldid=2942617"